TI Pharma Mid-Term Review Eindrapport

Committee via the TI Pharma website. The Mid-Term
Review Committee’s report shall be published on the
website of TI Pharma unless the Executive Board decides
otherwise.
Confidentiality and conflict of interest
Members of the Mid-Term Review Committee are
required to not divulge any information given to them
in the context of the Mid-Term Review, unless it has been
indicated by the Executive Board that the information
is public. Members of the Mid-Term Review Committee
shall sign a non-disclosure agreement before receiving
any information about TI Pharma projects and activities.
Members of the Mid-Term Review Committee must
not seek or act in any way to take undue advantage of,
or exercise undue influence on TI Pharma or any of its
partners. Members of the Mid-Term Review Committee
must inform TI Pharma of all conflicts interests, which
could be considered to affect their independence. When a
member of the Mid-Term Review Committee is in breach
of any of the requirements set out above, he/she will be
considered as no longer being in a position to stay as a
member of the Committee.
Information and facilities
The TI Pharma office shall provide the Mid-Term Review
Committee with all needed and appropriate information
and facilities to enable the Mid-Term Review Committee
to carry out its work.
Appendix 1 - Terms of reference
25